Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Early trials of atrial defect device promising:

This article was originally published in Clinica

Executive Summary

Closing atrial septal defects with a new catheter-based shunt worked in 98% of patients who had successful implants, according to an FDA Phase I trial of the device. The shunt, being developed by Texan firm Custom Medical Devices, was used on 46 patients of an average four years of age. After one year, 45 patients had sufficient closure, with 34 of these having full closure.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT080884

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel